Medtronic plc (MDT) Factsheet
Earnings-call transcript: none · IR deck: none — watch a real agent read these end-to-end →
Medtronic plc (MDT) Stock Analysis
Analysis from 10-Q filed 2026-09-03. Data as of Q3 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 7.0%. FCF margin 16.3%. D/E 0.6x. Source: 10-Q filed 2026-09-03.
| Metric | Value | Context |
|---|---|---|
| ROIC | 7.0% | Below expectations |
| FCF Margin | 16.3% | Strong cash generation |
| Debt/Equity | 0.6x | Moderate leverage |
ROIC 7.0% — Top 50% of sector peers. FCF margin 16.3% — Top 25%.
Explore Medtronic plc: Earnings History | Filings
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for MDT: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.
Profitability: Medtronic plc earns 7.0% ROIC, Top 50% in Healthcare
ROIC TTM 7.0%, sector median -7.5%, Top 50%. DuPont: NOPAT margin 14.4% × asset turnover 0.4x. Gross margin 65.0%. Operating margin 18.1%. Source: 10-Q filed 2026-09-03.
| Metric | MDT | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 7.0% | Warning | Above sector median of -7.5% |
| Return on Equity (ROE) | 10.7% | Adequate | Moderate equity returns |
| Gross Margin | 65.0% | Excellent | Strong pricing power |
| Operating Margin | 18.1% | Good | Efficient operations |
Cash Flow: Medtronic plc generates $6.1B FCF at 16.3% margin, positive NaN/8 quarters
FCF TTM $6.1B. FCF margin 16.3%, Top 25%. OCF/Net income 1.5x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2026-09-03.
| Metric | MDT | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 16.3% | Good | Excellent cash conversion |
| Free Cash Flow (TTM) | $6.1B | Good | Positive cash generation |
| OCF/Net Income | 1.5x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: Medtronic plc at 0.6x leverage, 9.4x interest coverage
Debt/Equity 0.6x. Total debt $28.2B, cash & investments $8.8B. Interest coverage 9.4x. Source: 10-Q filed 2026-09-03.
| Metric | MDT | Rating | Context |
|---|---|---|---|
| Debt to Equity | 0.6x | Good | Moderate leverage |
| Net Cash Position | $-19.3B | Warning | Net debt position |
| Interest Coverage | 9.4x | Good | Comfortable debt service |
Valuation: Medtronic plc trades at 21.3x earnings
P/E 21.3x. EV/Sales 3.5x. FCF yield 5.5%. Dividend yield 3.3%. Source: 10-Q filed 2026-09-03.
| Metric | MDT | Rating | Context |
|---|---|---|---|
| P/E Ratio | 21.3x | Adequate | Premium valuation |
| EV/Sales | 3.5x | Good | Growth premium priced in |
| FCF Yield | 5.5% | Good | Attractive cash return |
| Dividend Yield | 3.3% | Adequate | Meaningful income |
Capital Allocation: Medtronic plc returns 4.3% shareholder yield, reducing shares 0.1% YoY
Total shareholder yield 4.3% (div 3.3% + buyback 1.1%). Share count -0.1% YoY. Capital returned $4.8B TTM. Source: 10-Q filed 2026-09-03.
| Metric | MDT | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 4.3% | Good | Dividend + buyback yield combined |
| Buyback Yield | 1.1% | Adequate | Minimal buyback activity |
| Share Count Change (YoY) | -0.1% | Adequate | Net share reduction (accretive) |
| Total Capital Returned (TTM) | $4.8B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 7.0% | Top 50% | - |
| Free Cash Flow Margin | 16.3% | Top 25% | - |
| Gross Margin | 65.0% | Top 50% | 1.0x above |
| Operating Margin | 18.1% | Top 25% | - |
| Return on Equity (ROE) | 10.7% | Top 50% | - |
| P/E Ratio | 21.3x | N/A | - |
Financial Scorecard
| Metric | MDT | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 7.0% | Warning | Top 50% of sector (median: -7.5%) |
| Free Cash Flow Margin | 16.3% | Good | Top 25% of sector (median: 0.0%) |
| Gross Margin | 65.0% | Excellent | Top 50% of sector (median: 63.8%) |
| Debt to Equity Ratio | 56.0% | Good | Moderate leverage |
| P/E Ratio (Price-to-Earnings) | 21.3x | Adequate | Fair value |
| Free Cash Flow Yield | 5.5% | Good | Solid cash yield |
Frequently Asked Questions
Q: What is Medtronic plc's Return on Invested Capital (ROIC)?
Medtronic plc (MDT) has a trailing twelve-month Return on Invested Capital (ROIC) of 7.0%. The 8-quarter median ROIC is 6.8% with a improving trend. Sector median -7.5%. Source: 10-Q filed 2026-09-03.
Q: What is Medtronic plc's Free Cash Flow Margin?
Medtronic plc (MDT) has a free cash flow margin of 16.3%, generating $6.1 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2026-09-03.
Q: What is Medtronic plc's P/E ratio and how does it compare to peers?
Medtronic plc (MDT) trades at a P/E ratio of 21.3x, which is above the sector median of N/A. EV/Sales 3.5x. FCF yield 5.5%. Source: 10-Q filed 2026-09-03.
Q: Does Medtronic plc pay a dividend?
Medtronic plc (MDT) currently pays a dividend yield of 3.3%. Total shareholder yield (dividend + buybacks) 4.3%. Source: 10-Q filed 2026-09-03.
Q: How much debt does Medtronic plc have?
Medtronic plc (MDT) has a debt-to-equity ratio of 0.6x with total debt of $28.2 billion. Interest coverage 9.4x. Net debt $19.3 billion. Source: 10-Q filed 2026-09-03.
Q: What is Medtronic plc's revenue and earnings growth?
Medtronic plc (MDT) grew revenue by 9.8% year-over-year. EPS +12.2% YoY. Source: 10-Q filed 2026-09-03.
Q: Is Medtronic plc buying back stock?
Medtronic plc (MDT) repurchased $1.2 billion of stock over the trailing twelve months. This represents a buyback yield of 1.1%. Share count -0.1% YoY. Source: 10-Q filed 2026-09-03.
Q: How does Medtronic plc compare to competitors in Healthcare?
Compared to other companies in Healthcare, Medtronic plc (MDT) shows: ROIC 7.0%, sector median -7.5% (Top 50%). FCF margin 16.3%, sector median 0.0% (Top 25%). Gross margin 65.0%, 1.2pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with Medtronic plc?
No quantitative warning flags fired for Medtronic plc (MDT) on margin trend, FCF trend, ROIC trend, or leverage thresholds. Source: 10-Q filed 2026-09-03.
Data Source: Data sourced from 10-Q filed 2026-09-03. TTM metrics as of Q3 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.